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Introduction
Congestive heart failure (CHF) has become one of the 
most prominent health care problems in western coun-
tries. Increased prevalence of coronary artery disease 
(CAD), improvements in CAD, and hypertension treat-
ment, and aging of the population are major factors that 
1% to 2% of western populations suffer from CHF with a 
prevalence of 10% in the elderly (1,2).
Heart failure is a clinical syndrome, not a single disease 
entity that results from any number of structural or func-
tional conditions that cause diminished blood flow and 
decreased tissue oxygenation. Patients who have heart 
failure may present both signs and symptoms of volume 
overload, and inadequate tissue perfusion, or neither of 
them. Because many patients who have the syndrome do 
not present volume overload, the term ‘‘heart failure’’ is 
preferred to the more limited term CHF (3).
Two terms have ultimately emerged to define these pa-
tients. The term “acute decompensated heart failure” is 
used variably but usually describes those patients with 
known heart failure who experience acute or subacute de-
terioration of their heart failure state (4,5). The term “acute 
heart failure syndromes” emerged from 2004 and 2005 
meetings of an international workgroup which convened 
primarily to predict uniform terminology and definitions 
in heart failure (6). The workgroup defined acute heart 
failure syndromes as the “gradual or rapid deterioration 
in heart failure signs and symptoms resulting in a need 
for urgent therapy” (6). The consensus document further 
stated that these symptoms are primarily manifested from 
increased pulmonary density that result from elevated left 
ventricular filling pressures (with or without low cardiac 
output) and may occur in patients with normal or reduced 
left ventricular ejection fraction (6). The emergency de-
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Abstract
Objective: Congestive heart failure (CHF) has become one of the most important 
health care problems in western countries. This article focuses on the outpatient 
diagnosis and management of heart failure. We want to compare the outcome of 
patients who were treated with high dose diuretics in the emergency department 
(ED) without admission with patients who were admitted to hospital for standard 
treatment.
Methods: This was a randomized prospective clinical trial study. The patients who 
came to the ED from March 20, 2008 up to August 20, 2008 were divided into two 
groups randomly. The length of ED stay in the experimental group was documented. 
Also, readmission and mortality in 6 months and satisfaction in both groups were 
taken into consideration. All data were analyzed using SPSS 15.0.
Results: In experimental group, the rate of recurrent admission, expiration, 
discharge, clinic visit, and clinic admission was 8%, 4%, 29%, 18%, and 0% 
respectively. On the other hand, in control group it was 16%, 40%, 18%, 22%, and 
2% respectively. Additionally, there was a significant difference between these 
groups (P = 0.00).
Conclusion: This study is the first regional prospective trial to comprehensively 
examine the therapeutic management in patients with CHF. This study, comparing 
the high dose diuretic efficacy in the decreasing of hospital stay and readmission; and 
decreasing mortality rate with routine therapy, showed that there was a significant 
difference between these two strategies in the mortality rate, readmission, and 
length of hospital stay (P = 0.00).
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partment (ED) plays a serious role in the handling of acute 
heart failure syndromes since approximately 80% of  hos-
pitalized patient for the condition are admitted through 
the ED (5). Heart failure is progressive, and after recog-
nition of the syndrome, patients experience greater mor-
bidity and have more frequent encounters with the health 
care system. Heart failure results in an enormous cost to 
society in terms of morbidity, mortality, and health care 
expenditure. In 2005, the direct and indirect costs of heart 
failure were expected to reach $30 billion (7). The preva-
lence of heart failure is likely to increase with aging of the 
population and improved survival after myocardial infarc-
tion (MI). This article focuses on the outpatient diagnosis 
and management of heart failure. We want to compare the 
outcome of patients who are treated with high dose di-
uretics in the ED without admission with patients who are 
admitted to the hospital for standard treatment.
Methods 
This was a randomized prospective clinical trial study to 
compare two strategies in the treatment of CHF. All pa-
tients who came to the ED with a diagnosis of CHF, from 
March 20, 2008 up to August 20, 2008 were divided into 
two groups randomly. The length of ED stay in the ex-
perimental group was documented. Also, readmission 
and mortality in 6 months and satisfaction were recorded 
in a prepared form. The patients who had a history of 
CHF, those who were diagnosed with the physical exam, 
a chest x-ray, and echocardiography by the ED cardiolo-
gist were included in this study. The inclusion criteria was 
the exacerbation of CHF in II < NYHA. The patients with 
noncardiac dyspnea and acute coronary syndrome were 
excluded. The patients were divided into two groups. The 
control group was admitted to hospital wards and got 
routine treatment and the experimental group took the 
observation room in ED and got high dose lasix (higher 
than 100 mg). If patient’s blood pressure (BP ) > 100 we 
added trinitroglycerin (TNG) and captopril. Captopril 
dose increased to maximum (attention to tolerance). If 
patient’s BP < 100 we used inotropes too. We discharged 
the patients when (a) patients felt well; (b) patients could 
change position without orthostatic changes; (c) the rest 
pulse rate was lower than 100; (d) BP ≥ 85; (e) urinary out-
put ≥0.5 cc/kg/h; (f) O2 sat was higher than 90% in the 
room air; (g) cardiac troponin was lower than 0.1 ng/cc; 
(h) patients did not have any chest pain; and (i) patients 
did not have arrhythmia. Lasix dose in aggressive therapy 
in the experimental group started with 100 mg lasix and 
continued at a rate of 3-10 mg/h. We also we checked elec-
trolytes.
Data
Rehospitalization and death in 6 months were followed 
up by phone or clinic visits and the satisfaction rate was 
documented as well.
Data Analysis
All data were analyzed using SPSS version 15.0. Rates, 
means and standard deviation were used in order to pres-
ent the descriptive data. In order to compare the experi-
mental and control groups, chi-square and Student’s t-dis-
tribution were applied. 
Result
In this prospective clinical trial, the mean age in the exper-
imental and control groups were 67.4±13.5 and 68.1±12.2 
respectively (P = 0.793). Fifty six percent of patients in the 
experimental group were males and 44% were females. 
But this rate among males and females in the control 
group was 52% and 48% respectively (P = 0.688).
The frequency of dilated, diastolic, and ischemic cardio-
myopathy is shown in the Table 1.
Eleven, 23, and 16 patients in the experimental group 
stayed in the ED lower than 6 hours, 6 to 12 hours, and 
more than 12 hours respectively.
This shows that, there was a significant difference be-
tween routine treatment and aggressive ED therapy; and 
the outcome was better in aggressive ED group (Table 2). 
The satisfaction between these two groups did not have a 
significant difference (P = 0.058; Table 3).
Discussion 
This study is the first regional prospective trial to com-
prehensively examine the therapeutic management in pa-
tients with CHF. There are several unique aspects for this 
study: (a) it compares two treatment strategies; (b) the two 
strategies have clearly defined goals to reduce symptoms 
to NYHA ≤ II; (c) it includes a comprehensive analysis of 
Table 1. The frequency of cardiomyopathy
Dilated cardiomyopathy Diastolic dysfunction Ischemic cardiomyopathy P
Experimental 14 (28%) 7 (14%) 29 (58%) 0.134
Control 21 (42%) 10 (20%) 19 (38%)
Table 2. The outcomes in a six month follow up in both groups
Recurrent admission Expired Discharged Outpatient treatment Outpatient and admission P 
Experimental 1 (8%) 2 (4%) 29 (58%) 18 (36%) 0 (0%)
<0.05
Control 8 (16%) 20 (40%) 9 (18%) 11 (22%) 2 (4%)
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the hospital stay because the long length of stay due to 
high hospitalization rates and long-term dependency rep-
resent a major health care problem; (d) it includes the rate 
of death in a 6 month follow up; and (e) it shows the sat-
isfaction of these two treatment strategies. Besides these 
primary study objectives, the data collected will provide 
important information on less well known issues about 
CHF. Decompensated heart failure can be a complex 
treatment problem. Aggressive heart failure management 
protocols instituted in the observation unit have led to im-
proved patient outcomes and reduced hospital admission 
rates (8,9). Observation unit treatment protocols for pa-
tients presenting with acute decompensated heart failure 
include the implementation of diagnostic and therapeutic 
algorithms, cardiology department consultations, aggres-
sive nursing monitoring, detailed patient education, and 
follow-up arrangements made at discharge (8,10). Pa-
tients treated according to these protocols have benefited 
from lower 90-day ED revisit rates and decreased rates of 
rehospitalization (8). Although discharge evaluation is 
unique to each heart failure patient, ED observation unit 
discharge is appropriate only when certain basic criteria 
are met. For example, the patient should get an adequate 
response to diuretic therapy, as evidenced by a total net 
urine output of more than 1 L, and cardiac biomarkers 
should be within normal ranges. The patient should also 
have a stable electrolyte profile and no new clinically sig-
nificant arrhythmias, be ambulatory, and have a systolic 
blood pressure more than 95 mm Hg, and a resting pulse 
rate of less than 100 beats/min (9). Although no clinical 
trials exist to determine their effects on mortality, diuret-
ics persist as the mainstay of symptomatic treatment for 
heart failure. The reason is simple: heart failure is pre-
sented as a hypervolemic condition; therefore achieving 
euvolemia should improve symptoms. Thiazide diuretics 
are appropriate for patients who have mild symptoms, but 
most patients who have heart failure require loop diuret-
ics. Diuretics are indicated in all patients who have heart 
failure and who have signs of hypervolemia. For most out-
patients who are diuretic-naıve, furosemide 20 mg to 40 
mg (or its equivalent) once daily is a reasonable starting 
dose (11). The dose of diuretic should be adjusted so that 
symptoms of hypervolemia are controlled while maintain-
ing hemodynamic stability, renal function, and electrolyte 
balance. This tends to be an individualized trial-and-error 
(or trial-and-success) process. Diuretic resistance may 
result from several causes: progression of heart failure, 
excessive dietary sodium consumption, nonsterioidal 
anti-inflammatory drugs (NSAIDs), or anything else that 
reduces renal perfusion (11,12). If diuretic resistance is 
encountered, the first step is to increase the dose. The usu-
Table 3. Rate of satisfaction in both groups
Great Good Average Poor P 
Experimental 3 (6%) 38 (76%) 9 (18%) 0 (0%)
0.058
Control 0 (0%) 32 (64%) 16 (32%) 2 (4%)
al maximum single oral dose of furosemide is 200 mg to 
250 mg, or an equivalent dose of torsemide or bumetanide 
could be employed. Because the half-lives of loop diuretics 
are on the order of hours, frequent dosing may increase 
total daily diuresis (12). The concurrent use of an Angio-
tantion Enzyme Convector (ACE) inhibitor or aldoste-
rone antagonist may facilitate diuresis (13). In the clinical 
study that recruited patients with severe pulmonary ede-
ma and moderate-to-severe respiratory distress, Cotter et 
al (14) reported reduced rates of the composite outcome 
of hospital death, MI, and intubation among the patients 
receiving higher-dose nitrate therapy in the out-of-hos-
pital setting. In this study, 104 patients with acute heart 
failure syndrome were randomized by physicians working 
in the field with emergency medical services to get either 
low-dose furosemide and high-dose nitrates or high-dose 
furosemide and low-dose nitrates. Most of the study sub-
jects had a history of chronic heart failure, and there were 
no patients included with acute ST-elevation MI. All en-
rolled patients had rales on chest examination and a room 
air pulse oximetry of less than 90% when sitting upright. 
One study arm used high-dose nitrates (8-fold difference 
between study arms) and the other arm used high-dose 
furosemide (4-fold difference between study arms). The 
combined endpoint of hospital death, MI within 24 hours, 
and intubation within 12 hours was significantly lower in 
the high-dose nitrate group (25% versus 46%; P = 0.04). 
The most significant was the endotracheal intubation rate 
difference within the first 12 hours, with the high-dose ni-
trate treated patients requiring much less intubation than 
those receiving high-dose furosemide (13% versus 40%, 
P = 0.005). Additionally, significantly more patients were 
diagnosed with MI within the first 24 hours of admission 
in the high-dose furosemide group than the high dose 
nitrate group (37% and 17%, respectively, P = 0.05) (15). 
Observation unit strategies for the management of acute 
decompensated heart failure must result in reductions in 
hospital admissions and in the costs associated with the 
care of heart failure patients. Although recent improve-
ments in therapeutic options, including the regular use of 
ACE inhibitors and b-blockers have improved the progno-
sis for many patients with heart failure, episodes of severe 
decompensated heart failure do occur, requiring therapy 
that results in rapid symptomatic and hemodynamic sta-
bilization. Lasix in the observation unit has been proven 
to be safe and efficacious inpatients with acute decompen-
sated heart failure (16). In this study, we can find; (a) two 
groups were chosen randomly and the age, sex, and kind 
of heart failure was the same; and we excluded the patients 
with cardiogenic shock, BP dropped and ACS (b). The key 
of this study was the high dose of Lasix in the experimen-
tal group. Some studies have stated that it can be effective 
in the HF survival but they cannot say it definitely. On the 
other hand, the use of spironolactone make survival better 
in the chronic heart failure but there were not any stud-
ies about diuretics in acute HF. In this study, high dose of 
lasix used in a short time may decrease readmission and 
mortality by remodeling of heart chambers and changes 
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in the control system of epinephrine and RAS (3). Unfor-
tunately, from the start of this study we could not check 
the brain natriuretic peptide (BNP) and proBNP, but if we 
could do this; an observation of some changes in the neu-
rohormonal systems could be discerned (4). The number 
of patients to show a difference between these strategies to 
decrease mortality rate was enough, but to check it better 
some more studies are needed (5). Comparing the high 
dose diuretic efficacy in decreasing hospital stay and read-
mission and decreasing mortality rate with routine ther-
apy, showed that there is a significant difference between 
these two strategies in the mortality rate and readmission 
and length of hospital stay (P = 0.00).
Conclusion
According to this article, we found that, aggressive therapy 
of decompansative CHF can decrease the hospital stay and 
save the wards bed to more needed patients. This can also 
increase satisfaction by decreasing costs, saving time, re-
ducing readmission and finally increasing the prognosis.
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